M
Michael S. Gordon
Researcher at Pinnacle Financial Partners
Publications - 172
Citations - 13887
Michael S. Gordon is an academic researcher from Pinnacle Financial Partners. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 43, co-authored 153 publications receiving 12207 citations. Previous affiliations of Michael S. Gordon include GlaxoSmithKline & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
Michael S. Gordon,David S. Mendelson,Mitchell E. Gross,Mitchell E. Gross,Martina Uttenreuther-Fischer,Mahmoud Ould-Kaci,Yihua Zhao,Peter Stopfer,David B. Agus,David B. Agus +9 more
TL;DR: Afatinib was well tolerated with manageable side effects when administered once-daily, continuously at a dose of 40 mg, and Pharmacokinetic data showed no deviation from dose-proportionality and steady-state was reached on Day 8 at the latest.
Journal ArticleDOI
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
Beth A. Hellerstedt,Gerald Edelman,Nicholas J. Vogelzang,Harriet M. Kluger,Christopher A. Yasenchak,Xiaodong Shen,David A. Ramies,Michael S. Gordon,Primo N. Lara +8 more
TL;DR: This report reports on the metastatic NSCLC cohort which included patients who received prior EGFR and VEGF pathway targeted therapy, and evaluated activity and safety in 9 tumor types.
Journal ArticleDOI
Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
Andrea B. Apolo,John Allan Ellerton,Jeffrey R. Infante,Manish Agrawal,Michael S. Gordon,Raid Aljumaily,Carolyn D. Britten,Luc Dirix,Keun-Wook Lee,Matthew H. Taylor,Patrick Schöffski,Ding Wang,Alain Ravaud,Arnold B. Gelb,Junyuan Xiong,Galit Rosen,Manish R. Patel +16 more
TL;DR: New data is reported from a pooled analysis of pts with mUC from JAVELIN Solid Tumor (NCT01772004) and further characterize the clinical activity of avelumab in this disease.
Journal ArticleDOI
Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.
Manish R. Patel,John Allan Ellerton,Jeffrey R. Infante,Manish Agrawal,Michael S. Gordon,Raid Aljumaliy,Carolyn D. Britten,Luc Dirix,Keun-Wook Lee,Matthew H. Taylor,Patrick Schöffski,Ding Wang,Alain Ravaud,Arnold B. Gelb,Junyuan Xiong,Galit Rosen,Andrea B. Apolo +16 more
TL;DR: A planned interim pooled analysis of 2 cohorts from a large phase 1b trial of avelumab with promising efficacy and safety in patients with metastatic urothelial carcinoma is reported.
Journal ArticleDOI
Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro,Raoul Tibes,Michael S. Gordon,Bryan Y. Wong,Bryan Y. Wong,Joseph Paul Eder,Mitesh J. Borad,David S. Mendelson,Nicholas J. Vogelzang,Bruno R. Bastos,Bruno R. Bastos,Glen J. Weiss,Cristian Fernandez,William Sutherland,Hitoshi Sato,William E. Pierceall,David T. Weaver,Scott Slough,Ernesto Wasserman,Donald Kufe,Daniel D. Von Hoff,Takumi Kawabe,Sunil Sharma,Sunil Sharma +23 more
TL;DR: CBP501 is well tolerated in patients as monotherapy and with cisplatin and at the recommended phase II dose (RP2D), the combination is feasible and HRS manageable with prophylaxis.